Namdaroğlu Sinem, Tekgündüz Emre, Bozdağ Sinem Civriz, Durgun Gamze, Sarıca Abdurrahman, Demiriz Itır Şirinoğlu, Koçubaba Serife, Iskender Gülşen, Kayıkçı Omür, Altuntaş Fevzi
Ankara Oncology Education and Research Hospital, Hematology and Stem Cell Transplantation Clinic, Ankara, Turkey.
Transfus Apher Sci. 2013 Jun;48(3):403-6. doi: 10.1016/j.transci.2013.04.026. Epub 2013 May 8.
Microbial screening for contamination is a part of hematopoietic progenitor cell (HPC) collection and infusion procedure. We aimed to find out our microbial contamination rates during collection, processing and infusion steps of HPC products. We also evaluated the clinical course of patients who received contaminated HPC products.
PATIENTS-METHODS: We retrospectively analyzed microbial contamination records of HPC grafts between 2010 and 2012. HPC products of autologous donors were evaluated for contamination at three steps: at the end of mobilization, following processing with DMSO and just before stem cell infusion. Grafts of allogeneic donors were assessed only before HPC transplantation (HCT). Microbiological analysis of HPC samples were performed with an automated system (BacT/Alert®).
During the study period a total of 492 mobilization procedures were performed on 329 (214 autologous and 115 allogeneic) donors. Bacterial contamination has been detected in 103 of 1630 samples (6%). Ninety-seven out of 1162 blood samples (8%) from 265 patients who were treated with HCT were contaminated. Forty-six patients (41 autologous and 5 allogeneic) were transplanted with contaminated HPC products. During HCT 42 patients experienced febrile neutropenic attack and 34 of them had positive blood culture results. In none of these 34 patients the isolated pathogens were the same organisms with those found in the final contaminated stem cell product before stem cell infusion. None of the patients who received contaminated products died because of sepsis within the posttransplant 30days. There was no significant difference between patients who received contaminated and non-contaminated products in terms of the first day of fever, duration of fever, engraftment kinetics and duration of hospitalization.
Our results suggest that microbial contamination of HPC products is an issue to be prevented, although it may not have a major impact on the general success of HCT.
微生物污染筛查是造血祖细胞(HPC)采集和输注过程的一部分。我们旨在查明HPC产品在采集、处理和输注步骤中的微生物污染率。我们还评估了接受受污染HPC产品的患者的临床病程。
我们回顾性分析了2010年至2012年间HPC移植物的微生物污染记录。对自体供者的HPC产品在三个步骤进行污染评估:动员结束时、用二甲基亚砜处理后以及干细胞输注前。对同种异体供者的移植物仅在HPC移植(HCT)前进行评估。使用自动化系统(BacT/Alert®)对HPC样本进行微生物分析。
在研究期间,共对329名(214名自体供者和115名同种异体供者)供者进行了492次动员程序。在1630份样本中有103份(6%)检测到细菌污染。在接受HCT治疗的265名患者的1162份血样中有97份(8%)被污染。46名患者(41名自体患者和5名同种异体患者)接受了受污染的HPC产品移植。在HCT期间,42名患者发生发热性中性粒细胞减少发作,其中34名患者血培养结果呈阳性。在这34名患者中,没有一名患者分离出的病原体与干细胞输注前最终受污染的干细胞产品中发现的病原体相同。在移植后30天内,没有一名接受受污染产品的患者因败血症死亡。在发热第一天、发热持续时间、植入动力学和住院时间方面,接受受污染产品和未受污染产品的患者之间没有显著差异。
我们的结果表明,HPC产品的微生物污染是一个需要预防的问题,尽管它可能对HCT的总体成功率没有重大影响。